Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study)

Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study)

Abstract Background Chronic active antibody-mediated rejection (caAMR) in kidney transplants is associated with irreversible tissue damage and a leading cause of graft loss in the long-term. However, the treatment for caAMR remains a challenge to date. Recently, tocilizumab, a recombinant humanized...

Full description

Bibliographic Details
Main Authors: Lillian Streichart, Marie Felldin, Jana Ekberg, Lars Mjörnstedt, Per Lindnér, Annette Lennerling, Verena Bröcker, Johan Mölne, Jan Holgersson, Kristien Daenen, Lars Wennberg, Tomas Lorant, Seema Baid-Agrawal
Format: Article
Language:English
Published: BMC 2024-03-01
Series:Trials
Subjects:
Kidney transplantation
Chronic active antibody-mediated rejection
Donor-specific antibody
Interleukin-6
Tocilizumab
Treatment
Online Access:https://doi.org/10.1186/s13063-024-08020-0

Internet

https://doi.org/10.1186/s13063-024-08020-0

Similar Items